logo

Voyager Therapeutics (VYGR)



Trade VYGR now with
  Date
  Headline
1/22/2019 7:05:59 AM Voyager Therapeutics Appoints Robert Hesslein As General Counsel
1/7/2019 7:19:32 AM Voyager Therapeutics Provides Update To Its VY-AADC Clinical Program For Parkinson’s Disease
12/10/2018 7:11:43 AM Voyager First Patient Dosed In RESTORE-1, Phase 2 Trial Of VY-AADC Gene Therapy For Treatment Of Parkinson’s Disease
11/8/2018 8:53:26 AM Wedbush Is Lowering Voyager Therapeutics (VYGR) FY18 Rev. Estimate To 10.6 M From 13.5 M
11/8/2018 8:53:03 AM Wedbush Is Raising Voyager Therapeutics (VYGR) FY19 Estimate To -1.71 From -2.60
11/8/2018 8:52:41 AM Wedbush Is Increasing Voyager Therapeutics (VYGR) FY18 Estimate To -2.66 From -3.33
11/8/2018 8:52:26 AM Wedbush Is Increasing Voyager Therapeutics (VYGR) Q4 18 Estimate To -0.61 From -1.03
11/8/2018 8:51:53 AM Wedbush Reiterates Voyager Therapeutics (VYGR) At Outperform With $18 Down From $28 Price Target
10/23/2018 7:04:28 AM Ablexis Announces License Agreement With Voyager Therapeutics
8/15/2018 6:00:46 AM Karuna Appoints Steven Paul As CEO
8/8/2018 9:47:22 AM Wedbush Is Lowering Voyager Therapeutics (VYGR) FY18 Rev. Estimate To 13.5 M From 15.9 M
8/8/2018 9:47:03 AM Wedbush Is Cutting Voyager Therapeutics (VYGR) FY19 Estimate To -2.60 From -2.38
8/8/2018 9:46:49 AM Wedbush Is Lowering Voyager Therapeutics (VYGR) FY18 Estimate To -3.33 From -2.89
8/8/2018 9:46:34 AM Wedbush Is Lowering Voyager Therapeutics (VYGR) Q3 18 Estimate To -0.87 From -0.75
7/17/2018 7:05:01 AM Voyager Therapeutics Gets FDA Guidance On Development Path For VY-AADC And Provides Clinical Update
6/28/2018 4:33:14 PM Voyager Therapeutics Appoints Andre Turenne As President And CEO
6/21/2018 7:10:27 AM Voyager Therapeutics Says FDA Regenerative Medicine Advanced Therapy Designation Granted For VY-AADC